A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
Phase of Trial: Phase I
Latest Information Update: 08 May 2018
At a glance
- Drugs PRX 004 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions; First in man
- Sponsors Prothena
- 08 May 2018 According to a Prothena media release, the company initiated the study in the second quarter of 2018 and preliminary data from this study is expected in 2019.
- 08 May 2018 Status changed from not yet recruiting to recruiting, according to a Prothena media release.
- 16 Nov 2017 According to a Prothena media release, this study is expected to initiate by mid-2018.